Showing results (31-40 of 137) with videos related to
Sort By:
Pageof 14
IEEE Transactions on Pattern Analysis and Machine Intelligence|September 10, 2015
Generalized Flows for Optimal Inference in Higher Order MRF-MAPChetan Arora, Subhashis Banerjee, Prem Kumar Kalra, et al.The Indian Journal of Radiology & Imaging|June 24, 2024
Reproducibility and Explainability of Deep Learning in Mammography: A Systematic Review of LiteratureDeeksha Bhalla, Krithika Rangarajan, Tany Chandra, et al.Journal of Clinical Orthopaedics and Trauma|August 11, 2020
An audit of admissions and mortality of orthopedic indoor patients in a tertiary care hospital of IndiaSubhashis Banerjee, Gautham Suresh, Abhijit B Kale, et al.Steroids|November 21, 2013
Recent insights into non-nuclear actions of estrogen receptor alphaSubhashis Banerjee, Ken L Chambliss, Chieko Mineo, et al.Archives of Biochemistry and Biophysics|March 21, 2003
Cytochrome b5 reductase and cytochrome b5 support the CYP2E1-mediated activation of nitrosamines in a recombinant Ames testVishwesh Mokashi, Li Li, Todd D PorterThe Journal of Steroid Biochemistry and Molecular Biology|July 19, 2011
7-Dehydrocholesterol reductase activity is independent of cytochrome P450 reductaseLing Zou, Li Li, Todd D PorterFrontiers in Physiology|March 12, 2014
Cholesterol binding to ion channelsIrena Levitan, Dev K Singh, Avia Rosenhouse-DantskerCurrent Problems in Diagnostic Radiology|May 26, 2022
Basic principles of AI simplified for a Medical Practitioner: Pearls and Pitfalls in Evaluating AI algorithmsDeeksha Bhalla, Anupama Ramachandran, Krithika Rangarajan, et al.Dermatology and Therapy|September 16, 2024
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis TrialIan M Catlett, Lu Gao, Yanhua Hu, et al.The Journal of Dermatology|March 8, 2023
Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trialShinichi Imafuku, Yayoi Tada, Lauren Hippeli, et al.Pageof 14